ATHENS, Greece, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Rubico Inc. ("Rubico" or the "Company") (Nasdaq: RUBI), a global provider of shipping transportation services specializing in the ownership of vessels, today announced the pricing of its public offering of 6,666,666 units, each consisting of one share of the Company's common stock (or pre-funded warrants in lieu thereof) and 1.5 Class B Warrants to purchase shares of common stock, at a public offering price of $0.60 per unit. Each Class B Warrant is immediat ...

As filed with the United States Securities and Exchange Commission on January 7, 2026. Registration No. 333-[ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _____________________________________ Willow Lane Acquisition Corp. II (Exact name of registrant as specified in its charter) _____________________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdiction of | (Primary St ...

Core Viewpoint - Investors are optimistic about a new public offering of Freddie Mac and the potential for its release from government conservatorship [1] Group 1 - The anticipation surrounding Freddie Mac's public offering indicates a growing confidence in the housing finance market [1] - The eventual release from government conservatorship is seen as a significant milestone for Freddie Mac, potentially unlocking value for investors [1]

Core Viewpoint - C3is Inc. has successfully closed a public offering, raising approximately $9 million to support its capital expenditures and general corporate purposes [1][3]. Offering Details - The offering consisted of 7,500,000 units, each including either one Common Share or one Pre-Funded Warrant, along with Class D and Class E Warrants [2]. - The public offering price was set at $1.20 per unit for Common Shares and $1.19999 per unit for Pre-Funded Warrants, with the Pre-Funded Warrants being immediately exercisable [2]. - Class D Warrants have an initial exercise price of $1.20 and are exercisable immediately, expiring 60 months after issuance [2]. - Class E Warrants have an exercise price of $0.00001 and are also immediately exercisable [2]. Use of Proceeds - The net proceeds from the offering will be utilized for capital expenditures, including the acquisition of additional vessels, working capital, and other general corporate purposes [3]. Company Overview - C3is Inc. is a ship-owning company that provides dry bulk and crude oil seaborne transportation services, owning four vessels with a total fleet capacity of 213,464 deadweight tons [6].

Core Points - C3is Inc. announced a public offering expected to generate approximately $9 million in gross proceeds before expenses [1][3] - The offering consists of 7,500,000 units, each including one Common Share or one Pre-Funded Warrant, along with Class D and Class E Warrants [2] - The transaction is anticipated to close on or about December 12, 2025, subject to customary closing conditions [3] Offering Details - Each unit in the offering is priced at $1.20 for a Common Share and $1.19999 for a Pre-Funded Warrant, with the Pre-Funded Warrants being immediately exercisable [2] - Class D Warrants have an initial exercise price of $1.20 per Common Share and are exercisable immediately, expiring 60 months after issuance [2] - Class E Warrants have an exercise price of $0.00001 per Common Share and are also immediately exercisable [2] Use of Proceeds - The net proceeds from the offering will be used for capital expenditures, including the acquisition of additional vessels, working capital, and other general corporate purposes [3] Company Overview - C3is Inc. is a ship-owning company that provides dry bulk and crude oil seaborne transportation services, owning four vessels with a total fleet capacity of 213,464 deadweight tons [6]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - ITT Inc. has announced a public offering of 7,000,000 shares of common stock at a price of $167.00 per share, with an additional option for underwriters to purchase up to 1,050,000 shares [1][2] Group 1: Offering Details - The estimated net proceeds from the offering are approximately $1.14 billion after deducting underwriting discounts and commissions, which will be used to fund a portion of the acquisition of SPX FLOW, Inc. [2] - The offering is expected to close on December 10, 2025, subject to customary closing conditions [1][2] - Goldman Sachs & Co. LLC and UBS Investment Bank are acting as lead book-running managers for the offering [3] Group 2: Regulatory Information - The offering is made pursuant to an automatic shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [4] - The preliminary prospectus supplement and accompanying base prospectus have been filed with the SEC and are available on the SEC's website [4] Group 3: Company Overview - ITT is a diversified manufacturer of critical components and customized technology solutions for transportation, industrial, and energy markets [6] - The company is headquartered in Stamford, Connecticut, and operates in over 35 countries with sales in approximately 125 countries [6]

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million of American depositary shares (ADSs), each representing three ordinary shares, or for certain investors that so choose, in ...

Core Viewpoint - Fulcrum Therapeutics, Inc. has initiated an underwritten public offering of $150 million in common stock, with an option for underwriters to purchase an additional $22.5 million [1][2]. Group 1: Offering Details - The offering is being managed by J.P. Morgan, Leerink Partners, Cantor, Oppenheimer & Co., and Truist Securities [2]. - The shares are being offered under an effective shelf registration statement filed with the SEC on February 27, 2024, and declared effective on April 25, 2024 [3]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3][5]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for general corporate purposes, including working capital, capital expenditures, research and development expenses, and potential acquisitions or investments [4]. Group 3: Company Overview - Fulcrum Therapeutics is focused on developing small molecules for patients with genetically defined rare diseases, with its lead program being pociredir for sickle cell disease [7]. - The company utilizes proprietary technology to identify drug targets that can modulate gene expression [7].

Core Viewpoint - Kestra Medical Technologies, Ltd. has announced an upsized underwritten public offering of 6,000,000 common shares priced at $23.00 per share, aiming for gross proceeds of $138 million before expenses [1]. Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage company focused on wearable medical devices and digital healthcare, specifically targeting improvements in patient outcomes for cardiovascular diseases through innovative monitoring and therapeutic technologies [6]. Offering Details - The offering is expected to close on December 4, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 900,000 common shares at the public offering price [1]. - The offering is being managed by BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC, and Wells Fargo Securities as bookrunners [2].